Christopher J. Mengler

Christopher J. Mengler

Director Ejecutivo en CUDA Pharmaceuticals, Inc. .

61 años
Health Technology
Consumer Services
Commercial Services

Perfil

Christopher J.
Mengler
is the founder of CUDA Pharmaceuticals, Inc. He is currently a member of The Rho Chi Society.
Previously, he worked as a Director-Project Management at Pfizer Inc. and as an Executive Vice President-Global Strategic Planning at Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc. He was also the President-Global Pharmaceuticals Division at Impax Laboratories LLC from 2009 to 2010.
Mr. Mengler has an undergraduate degree from The Johns Hopkins University and St. John's University, and an MBA from Baruch College.

Cargos activos de Christopher J. Mengler

EmpresasCargoInicio
The Rho Chi Society Corporate Officer/Principal 14/06/2010
Director Ejecutivo -
Todos los cargos activos de Christopher J. Mengler

Antiguos cargos conocidos de Christopher J. Mengler.

EmpresasCargoFin
Corporate Officer/Principal 19/10/2010
Corporate Officer/Principal -
Corporate Officer/Principal -
PFIZER, INC. Corporate Officer/Principal -
BARR PHARMACEUTICALS INC Corporate Officer/Principal -
Ver el detalle de la experiencia de Christopher J. Mengler.

Formación de Christopher J. Mengler.

The Johns Hopkins University Undergraduate Degree
St. John's University Undergraduate Degree
Baruch College Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Christopher J. Mengler.

Relaciones

6

Relaciones de 1er grado

10

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas1
PFIZER, INC.

Health Technology

Empresas privadas6

Health Technology

Health Technology

Health Technology

Commercial Services

The Rho Chi Society

Health Technology

Ver las conexiones de la empresa
  1. Bolsa de valores
  2. Insiders
  3. Christopher J. Mengler
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA